Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: inv
about
Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients.IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profileIn situ analysis of the variable heavy chain gene of an IgM/IgG-expressing follicular lymphoma: evidence for interfollicular trafficking of tumor cells.Prenatal origin of childhood AML occurs less frequently than in childhood ALL.Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review.The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemiaDetermination of minimal residual disease in leukaemia patients.The ontogeny and fate of NK cells marked by permanent DNA rearrangements.Evaluation of T cell receptor testing in lymphoid neoplasms: results of a multicenter study of 29 extracted DNA and paraffin-embedded samples.Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders.Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.Minimal residual disease in acute lymphoblastic leukemiaAssociation of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemiaDetermining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groupsStatus of minimal residual disease testing in childhood haematological malignanciesGene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemiaRole of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Evolution of Tumor Clones in Adult Acute Lymphoblastic Leukemia.Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment.Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis.Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.Comparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemiaCytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models.Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group.Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia.Clinical Impact of Genomic Information in Pediatric Leukemia.Characteristic expansion of CD45RA CD27 CD28 CCR7 lymphocytes with stable natural killer (NK) receptor expression in NK- and T-cell type lymphoproliferative disease of granular lymphocytes.Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation.Remission is good - relapse is bad.Multiplex PCR reaction for the detection and identification of immunoglobulin kappa deleting element rearrangements in B-lineage leukaemias.Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype.Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia.
P2860
Q24801607-0089E637-4E70-47FF-A16F-E3F666DBAD4EQ27851563-B9FD1995-0652-4D98-83A1-61095B1BC0D7Q28476476-19C9B520-710C-4651-8180-BB92113662F6Q30826654-8964AEB2-5ACC-481D-9B68-8DC920763824Q33240663-919057D0-7983-4950-9E8C-7AEA52D9B8E2Q33588450-52FE452A-BC07-4762-B090-4FEAFDF95279Q34448334-66CA9DEF-168D-4A68-8BA8-7D0BB5771D49Q35094049-DBDFD668-AC80-43D0-8CEE-5A89C62CBDD1Q35145184-BF548EFE-9904-4ABF-A025-E2F08DAEE9CEQ35737793-D0F40DCB-8ECC-43DB-A3A1-3FD845804F64Q35869347-FC0A3A06-2D8A-4882-8AE9-183AFFC7276CQ35976588-05CCFA4D-BED4-457A-B239-3E8C3B30A02CQ36153422-D28AC523-29BF-41C3-B09A-4C8AA7DE7F12Q36366977-FEF40F50-2CDF-4CF6-B34B-937EC2A09A02Q36713493-77D40C1B-8589-4A9B-9E53-03A03C11CBD0Q37077352-93191901-DCB6-40F5-9EC6-4DA1D6E3DADFQ37101299-9C25A8A2-9B88-43F1-B76C-B0265035F3FAQ37148110-EDEB7532-720E-4366-920C-692F4C342479Q37164456-585F1009-6AD7-4705-9B2C-A9398E26DE45Q37207757-9F1B6A5D-FBEC-404E-BA05-BABDAEC9D625Q37246360-0D9DF2F9-A8A0-4BB2-8233-6A87326307F6Q37320718-5CE6603C-656F-4373-9728-AF037E204F18Q37389544-DA9C6BBE-43B6-4254-8E0C-931342377CACQ37544878-27B42FF6-89FD-41F7-A0BE-B6C1A420252FQ37650740-EF32472C-DCF8-40E6-8348-06DB44962784Q38055164-05F3EBE1-7658-43AB-8D7D-36F32C46BE0BQ39646177-14B018A5-BE30-4D14-845E-A0387E6889C8Q41781135-4C83EB40-098F-4FAF-82E2-905DCAE04849Q41986599-464DDD2A-3105-4B1F-B17D-FA238EB66E02Q42174988-9E8F868A-35BF-4B7A-ACCF-7C0E807B8413Q43087326-A861FE2D-37F9-4E1A-AD90-41EFCD8889CCQ44505579-C97CAA43-4DB4-4AA2-BCFA-98ED89632BB7Q47221791-E47F1F48-CCD3-46DF-9784-69ED127BC21EQ47339203-B8CB88FC-01FB-4879-BF27-179D648F584CQ48028225-75203D68-38DB-4D79-9AEE-9A55EB9594E4Q49305200-0E8FD58D-ED1B-4340-BD09-B1A91900398FQ50756871-1022584D-B721-449C-BFB1-09FD933999B5Q51917960-71AB4255-0AC9-4E19-9F5A-37B252CF647FQ54605226-5383781A-B0EB-447A-A04C-30E8DA66602E
P2860
Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: inv
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Primers and protocols for stan ...... BIOMED-1 CONCERTED ACTION: inv
@en
type
label
Primers and protocols for stan ...... BIOMED-1 CONCERTED ACTION: inv
@en
prefLabel
Primers and protocols for stan ...... BIOMED-1 CONCERTED ACTION: inv
@en
P2093
P356
P1433
P1476
Primers and protocols for stan ...... BIOMED-1 CONCERTED ACTION: inv
@en
P2093
Bartram CR
Gonzalez M
Panzer-Grümayer ER
Pongers-Willemse MJ
San Miguel JF
P2888
P304
P356
10.1038/SJ/LEU/2401245
P577
1999-01-01T00:00:00Z
P6179
1056650243